Picture of Defence Therapeutics logo

DTC Defence Therapeutics Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-15.76%
3m-25.26%
6m-42.62%
1yr-59.85%
Volume Change (%)
10d/3m-10.73%
Price vs... (%)
52w High-55.32%
50d MA-11.81%
200d MA-31.72%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Defence Therapeutics EPS forecast chart

Profile Summary

Defence Therapeutics Inc. is a Canada-based biotechnology company working on engineering vaccines and antibody drug conjugates (ADC) products using its proprietary platform. The Company is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. Its platform's core is the Accum technology, which enables delivery of vaccine antigens or ADCs in their intact form to target cells. The Company is focused on research, development and advancement of various products using its Accum technology, which include Dendritic Cell cancer vaccines using Accum (Accuvac); a new protein-based vaccine formulation against COVID and infectious diseases; ADC targeting various cancers; anti-cancer AccuTOX program; cervical cancer vaccine; mesenchymal stromal cell-based vaccine (ARM) targeting cancer, and messenger ribonucleic acid vaccination.

Directors

    Last Annual
    June 30th, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    July 10th, 2020
    Public Since
    May 7th, 2021
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    ca flag iconCanadian Securities Exchange
    Shares in Issue
    45,036,673
    Blurred out image of a map
    Address
    1680-200 Burrard Street, VANCOUVER, V6C 3L6
    Web
    Phone
    +1 5149472272
    Auditors
    Crowe MacKay LLP

    DTC Share Price Performance

    Similar to DTC

    Picture of Albert Labs International logo

    Albert Labs International

    ca flag iconCanadian Securities Exchange

    Picture of Algernon Pharmaceuticals logo

    Algernon Pharmaceuticals

    ca flag iconCanadian Securities Exchange

    Picture of Alpha Cognition logo

    Alpha Cognition

    ca flag iconCanadian Securities Exchange

    Picture of Asep Medical Holdings logo

    Asep Medical Holdings

    ca flag iconCanadian Securities Exchange

    Picture of Awakn Life Sciences logo

    Awakn Life Sciences

    ca flag iconCanadian Securities Exchange

    FAQ